Prevalence and antifungal drug resistance of nosocomial Candida species isolated from two university hospitals in Egypt

Document Type : Original Articles


1 Microbiology and Immunology Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt

2 Microbiology Department, Faculty of Pharmacy and Pharmaceutical Industries, Sinai University, Kantara, Egypt



Background and Purpose: There is a significant rise in morbidity and mortality of infections caused by Candida. Candida spp. infections are currently ranked fourth among nosocomial infections which are difficult to diagnose and refractory to therapy.Given the differences in susceptibility among various spp., identification of Candida spp. is an important step that leads to the selection of a suitable antifungal.
Materials and Methods: A prevalence study was on 122 Candida isolates. The Candida spp. were identified using Chromogenic agar and polymerase chain reaction (PCR). The antifungal susceptibility (AFS) of Candida spp. to amphotericin B, fluconazole,voriconazole, and caspofungin was determined by the disc diffusion method.
Results: In total, 122 Candida clinical isolates were investigated in this study. Candida albicans with 57.4% (70 isolates) had the highest prevalence rate, while 52 isolates (42.6%) were non-albicans Candida species (NAC). The NAC include Candida krusei (20.4%), Candida tropicalis (6.5%), Candida parapsilolsis (5.7%), Candida dubliniensis (4.9%), and Candida glabrata (4.9%). The AFS showed that the resistance rates of Candida spp. to fluconazole and voriconazole were 13.1% (16 isolates) and 9.8% (12 isolates), respectively. Moreover, only five isolates (4.1%) were resistant to caspofungin. Furthermore, there was no resistance against amphotericin B. The spp. that showed the highest resistance were C. glabrata and C. tropicalis, while the lowest resistance was observed in C. albicans and C. dubliniensis.
Conclusion: In conclusion, rapid identification of clinical Candida isolates and standard AFS are essential procedures for controlling the rise of resistant NAC clinical settings. Usage of fluconazole should be restricted, especially in patients with recurrent Candida infections.


1. Xiao Z, Wang Q, Zhu F, An Y. Epidemiology, species
distribution, antifungal susceptibility and mortality risk factors
of Candidemia among critically ill patients: a retrospective study
from 2011 to 2017 in a teaching hospital in China. Antimicrob
Resist Infect Control. 2019; 8:89.
2. Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug
resistance among
Candida species: mechanisms and clinical
impact. Mycoses. 2015; 58(Suppl 2):2-13.
3. Aboualigalehdari E, Ghafourian S, Sadeghifard N, Sekawi Z. Is
Candida albicans a cause of nosocomial infection in Iran? Rev
Med Microbiol. 2013; 24(4):85-8.
4. Seyoum E, Bitew A, Mihret A. Distribution of
Candida albicans
and non-albicans Candida species isolated in different clinical
samples and their in vitro antifungal suscetibity profile in
Ethiopia. BMC Infect Dis. 2020; 20(1):231.
5. Hesstvedt L, Gaustad P, Andersen CT, Haarr E, Hannula R,
Haukland HH, et al. Twenty-two years of Candidaemia
surveillance: results from a Norwegian national study. Clin
Microbiol Infect. 2015; 21(10):938-45.
6. Abass E, Mohamed S, El-Kholy I, Zaki S. Incidence of ICUacquired candidemia in a tertiary care hospital in Cairo,
Egypt J Microbiol. 2019; 54(1):55-61.
7. Kadry AA, El-Ganiny AM, El-Baz AM. Comparison of methods
used in identification of
Candida albicans. Res J Pharm
Technol. 2018; 11(3):1164-8.
8. Baradkar VP, Mathur M, Kumar S. Hichrome candida agar for
identification of
Candida species. Indian J Pathol Microbiol.
2010; 53(1):93-5.
9. Murray CK, Beckius ML, Green JA, Hospenthal DR. Use of
chromogenic medium for the isolation of yeasts from clinical
specimens. J Med Microbiol. 2005; 54(Pt 10):981-5.
10. Chang HC, Leaw SN, Huang AH, Wu TL, Chang TC. Rapid
identification of yeasts in positive blood cultures by a multiplex
PCR method. J Clin Microbiol. 2001; 39(10):3466-71.
11. Carvalho A, Costa-De-Oliveira S, Martins ML, Pina-Vaz C,
Rodrigues AG, Ludovico P, et al. Multiplex PCR identification
of eight clinically relevant
Candida species. Med Mycol. 2007;
12. Bassetti M, Peghin M, Timsit JF. The current treatment
landscape: candidiasis. J Antimicrob Chemother. 2016; 71(Suppl
13. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV,
Keniya MV, et al. Efflux-mediated antifungal drug resistance.
Clin Microbiol Rev. 2009; 22(2):291-321.
14. Perlin DS, Shor E, Zhao Y. Update on antifungal drug
resistance. Curr Clin Microbiol Rep. 2015; 2(2):84-95.
15. Bhattacharjee P. Epidemiology and antifungal susceptibility of
Candida species in a tertiary care hospital, Kolkata, India. Curr
Med Mycol. 2016; 2(2):20-7.
16. Cornet M, Sendid B, Fradin C, Gaillardin C, Poulain D, Nguyen
HV. Molecular identification of closely related
Candida species
using two ribosomal intergenic spacer fingerprinting methods. J
Mol Diagn. 2011; 13(1):12-22.
17. Clinical and Laboratory Standards Institute (CLSI). Method for
anti-fungal disk diffusion susceptibility testing of yeasts:
approved guideline. 2
nd ed. Wayne, PA: Clinical and Laboratory
Standards Instituite; 2009.
18. Scorzoni L, de Paula E Silva AC, Marcos CM, Assato PA, de
Melo WC, de Oliveira HC, et al. Antifungal therapy: new
advances in the understanding and treatment of mycosis. Front
Microbiol. 2017; 8:36.
19. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis:
a persistent public health problem. Clin Microbiol Rev. 2007;
20. Daef E, Moharram A, Eldin SS, Elsherbiny N, Mohammed M.
Evaluation of chromogenic media and semi-nested PCR in the
identification of
Candida species. Braz J Microbiol. 2014;
21. Hassan MH, Ismail MA, Moharram AM, Shoreit M. Prevalence
of vaginal infection by multidrug resistant
Candida species
among different ages in Egypt. Am J Microbiol Res. 2017;
22. Khairat SM, Sayed AM, Nabih M, Soliman NS, Hassan YM.
Prevalence of
Candida blood stream infections among
children in tertiary care hospital: detection of species and
antifungal susceptibility. Infect Drug Resist. 2019; 12:
23. Kaur R, Dhakad MS, Goyal R, Kumar R. Emergence of
nonalbicans Candida species and antifungal resistance in
intensive care unit patients. Asian Pac J Trop Biomed. 2016;
24. Kothavade RJ, Kura MM, Valand AG, Panthaki MH.
: its prevalence, pathogenicity and increasing resistance
to fluconazole. J Med Microbiol. 2010; 59(8):873-80.
25. Reichart PA, Samaranayake LP, Samaranayake YH, Grote M,
Pow E, Cheung B. High oral prevalence of
Candida krusei in
leprosy patients in Northern Thailand. J Clin Microbiol. 2002;
26. Hope W, Morton A, Eisen DP. Increase in prevalence of
non-Candida albicans candidaemia and the
association of
Candida krusei with fluconazole use. J Hosp
Infect. 2002; 50(1):56-65.
27. Sandhya Rani T, Srikumar R, Reddy EP, Latha S. Prevalence
and characterization of opportunistic candidal infection among
patients with type II diabetes mellitus. Indian J Public Health.
2019; 10(7):448-58.
28. Sharma Y, Chumber SK, Kaur M. Studying the prevalence,
species distribution, and detection of in vitro production of
phospholipase from
Candida isolated from cases of invasive
candidiasis. J Global Infect Dis. 2017; 9(1):8-11.
29. Yang CW, Barkham TM, Chan FY, Wang Y. Prevalence of
Candida species, including Candida dubliniensis, in Singapore.
J Clin Microbiol. 2003; 41(1):472-4.
30. Esmat MM, Mohamed T, Abdelrahman AH. Species
identification and antifungal susceptibility profile of
isolates from ICU patients in Sohag University Hospital, Upper
Egypt. Egypt J Med Microbiol. 2015; 38(3676):1-9.
31. Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and
diversity in cystic fibrosis patients over a 5-year period in a
national reference center. Med Mycol. 2016; 54(8):781-6.
32. Al Shakirchi M, Klingspor L, Bergman P, Hjelte L, de
Monestrol I. A 16-year retrospective study on fungal prevalence
and diversity in patients with Cystic Fibrosis-
was associated with a decline in lung function. Int J
Infect Dis. 2020; 96:663-70.
33. Vermitsky JP, Edlind TD. Azole resistance in
Candida glabrata:
coordinate upregulation of multidrug transporters and evidence
for a Pdr1-like transcription factor. Antimicrob Agents
Chemother. 2004; 48(10):3773-81.
34. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS,
Rogers PD. Azole antifungal resistance in
Candida albicans and
non-albicans Candida species. Front Microbiol. 2017;
35. Yoo JI, Choi CW, Lee KM, Kim YK, Kim TU, Kim EC, et al.
National surveillance of antifungal susceptibility of
species in South Korean hospitals. Med Mycol. 2009;
36. Berkow EL, Lockhart SR. Fluconazole resistance in
species: a current perspective. Infect Drug Resist. 2017;
37. Perlin DS. Echinocandin resistance in
Candida. Clin Infect Dis.
2015; 61(Suppl 6):S612-7.
38. Bitew A, Abebaw Y. Vulvovaginal candidiasis: species
distribution of
Candida and their antifungal susceptibility
pattern. BMC Womens Health. 2018; 18(1):94.
39. Kadry AA, El-Ganiny AM, El-Baz AM. Relationship between
Sap prevalence and biofilm formation among resistant clinical
isolates of
Candida albicans. Afr Health Sci. 2018;
40. Pristov KE, Ghannoum MA. Resistance of
Candida to azoles
and echinocandins worldwide. Clin Microbiol Infect. 2019;
41. Khan Z, Ahmad S, Mokaddas E, Meis JF, Joseph L, Abdullah A,
et al. Development of echinocandin resistance in
following short-term exposure to caspofungin  for empiric therapy. Antimicrob Agents Chemother. 2018;
42. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of
clinical experience. J Infect Dis. 1990; 12(2):308-29.
43. Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L,
Lindquist S. Fitness trade-offs restrict the evolution of resistance
to amphotericin B. PLoS Biol. 2013; 11(10):e1001692.